DexCom down 6% as post Q2 earnings release slump continues

[DexCom headquarters in San Diego, CA, USA.]
JHVEPhoto/iStock Editorial via Getty Images

* DexCom (NASDAQ:DXCM [https://seekingalpha.com/symbol/DXCM]) is down ~6% in Monday trading, continuing a downward trend that began in late July following the release [https://seekingalpha.com/news/4474824-dexcom-falls-despite-results-beat-revenue-outlook-raise] of its Q2 financial results.
* While there doesn't appear to be a clear catalyst for today's decline, DexCom was trading above $89 per share just before the July 30 earnings release. On Monday, the price dropped to as low as $77.10 per share.
* While DexCom's Q2 results beat on both lines and it raised its 2025 revenue guidance, the stock fell after the closing bell on July 30.
* The maker of continuous glucose monitors did report that its non-GAAP gross margin fell to 60.1% from 63.5% in the year-ago period.
* A look at insider transactions finds that over the last six months, there have been net share purchases [https://finance.yahoo.com/quote/DXCM/insider-transactions/] (accounting for shares sold) of ~316K shares.

MORE ON DEXCOM

* DexCom, Inc. 2025 Q2 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4806488-dexcom-inc-2025-q2-results-earnings-call-presentation]
* DexCom, Inc. (DXCM) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4806487-dexcom-inc-dxcm-q2-2025-earnings-call-transcript]
* DexCom: Delivering Consistent Growth [https://seekingalpha.com/article/4802712-dexcom-delivering-consistent-growth]
* DexCom raises 2025 revenue guidance to $4.625B as type 2 non-insulin access expands [https://seekingalpha.com/news/4475058-dexcom-raises-2025-revenue-guidance-to-4_625b-as-type-2-non-insulin-access-expands]
* DexCom falls despite results beat, revenue outlook raise [https://seekingalpha.com/news/4474824-dexcom-falls-despite-results-beat-revenue-outlook-raise]